



Medical Pharmacy Drug Prior Authorization Criteria

Drug Trade Name:	Remicade, Inflectra, Renflexis, Avsola	Drug Generic Name:	Infliximab
J Code:	J1745, Q5103, Q5104, Q5121	1 billable unit =	10 mg
Original Date of Review:	12/7/2022	Last Reviewed:	9/11/2024
Revision Date History	12/7/2022, 3/15/2023, 8/30/2023, 12/13/2023		

Infliximab is a monoclonal antibody (chimeric IgG1 kappa) with specific activity for human tumor necrosis factor-alpha (TNF-alpha).

Criteria:

- **Length of authorization:**
 - Initial: 6 months
 - Renewal: Up to 12 months
- **Age: see below for product specific requirements**
- **Diagnoses [including ICD-10 codes]:**
- **Quantity Limit:**
 - **Loading dose**
 - Remicade/Infliximab 100mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)
 - Inflectra 100mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)
 - Renflexis 100mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)
 - Avsola 100mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)
 - **Maintenance Dose**
 - Remicade/Infliximab 100mg single-use vial: 10 vials every 4 weeks
 - Inflectra 100mg single-use vial: 10 vials every 4 weeks
 - Renflexis 100mg single-use vial: 10 vials every 4 weeks
 - Avsola 100mg single-use vial: 10 vials every 4 weeks
- **Maximum Units:**
 - **Loading dose**
 - Rheumatoid arthritis (RA): 40 billable units at weeks 0, 2, 6
 - All other indications (except management of immune checkpoint inhibitor toxicity): 60 billable units at weeks 0, 2, 6
 - Acute GVHD: 10 billable units at weeks 0, 1, 2, 3
 - Management of immune checkpoint inhibitor toxicity: 60 billable units at weeks 0, 2
 - **Maintenance dose**
 - Rheumatoid arthritis (RA): 100 billable units every 4 weeks
 - Crohn’s disease/Ulcerative colitis: 100 billable units every 8 weeks
 - Ankylosing spondylitis: 60 billable units every 6 weeks
 - All other indications (except management of immune checkpoint inhibitor toxicity): 60 billable units every 8 weeks
- **Initial Approval Criteria**
 - **Universal Criteria**
 - Patient has been evaluated and screened for the presence of hepatitis B virus (HBV) and/or serological status prior to initiating treatment; AND
 - Physician has assessed baseline disease severity utilizing an objective

measure/tool; AND

- Patient is up to date with all vaccinations, in accordance with current vaccination guidelines, prior to initiating therapy; AND
- Patient is at least 18 years of age (unless otherwise specified); AND
- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and provider attests that ongoing monitoring for presence of TB is evaluated and considered in clinically appropriate scenarios; AND
- Provider attests that the patient will be screened for active infection, including clinically important localized infections, prior to each administration of this medication; AND
- Must not be administered concurrently with live vaccines or therapeutic infectious agents (i.e., BCG bladder instillation for bladder cancer, etc.); AND
- Patient is not on concurrent treatment with another TNF-inhibitor, biologic response modifier or other non-biologic agent (i.e., apremilast, tofacitinib, baricitinib, etc.); AND
- Will not be used in patients with moderate or severe heart failure (i.e., New York Heart Association [NYHA] Functional Class III/IV) [Note: Only applies when doses >5mg/kg are used]; AND

○ **Indication Specific Criteria**

▪ **Crohn's Disease:**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; AND
- Documented moderate to severe disease; AND
- Documented failure, contraindication or ineffective response at maximum tolerated doses to a minimum three (3) month trial of corticosteroids or immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate) AND
- Patient is at least 6 years of age; AND

▪ **Ulcerative Colitis**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; AND
- Documented moderate to severe disease; AND
- Documented failure, contraindication or ineffective response at maximum tolerated doses to a minimum three (3) month trial of corticosteroids or immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate)

▪ **Pediatric Ulcerative Colitis**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; AND
- Documented moderate to severe disease; AND
- Patient is at least 6 years of age; AND
- Documented failure, contraindication or ineffective response at maximum tolerated doses to a minimum three (3) month trial of corticosteroids or immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate)

▪ **Fistulizing Crohn's Disease**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; AND
- Patient has at least one or more draining fistulas (i.e. enterovesical, enterocutaneous, enteroenteric, or enterovaginal fistulas) for at least 3

months

- **Rheumatoid Arthritis**
 - Must be prescribed by, or in consultation with, a specialist in rheumatology; AND
 - Documented moderate to severe disease; AND
 - Patient has had at least a 3-month trial and failed previous therapy with ONE oral disease modifying anti-rheumatic agent (DMARD) such as methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.; AND
 - Used in combination with methotrexate (MTX) unless contraindicated
- **Psoriatic Arthritis**
 - Must be prescribed by, or in consultation with, a specialist in dermatology or rheumatology; AND
 - Documented moderate to severe disease; AND
 - For patients with predominantly axial disease OR active enthesitis, a trial and failure of at least a 4-week trial of ONE (1) non-steroidal anti-inflammatory agents (NSAIDs), unless use is contraindicated; OR
 - For patients with peripheral arthritis or dactylitis, a trial and failure of at least a 3-month trial of ONE oral disease-modifying anti-rheumatic agent (DMARD) such as methotrexate, azathioprine, sulfasalazine, hydroxychloroquine, etc.
- **Ankylosing Spondylitis**
 - Must be prescribed by, or in consultation with, a specialist in rheumatology; AND
 - Documented active disease; AND
 - Patient had an adequate trial and failure of at least TWO (2) non-steroidal anti-inflammatory agents (NSAIDs) over 4 weeks (in total), unless use is contraindicated
- **Plaque Psoriasis**
 - Must be prescribed by, or in consultation with, a specialist in dermatology or rheumatology; AND
 - Documented moderate to severe plaque psoriasis for at least 6 months with at least one of the following:
 - Involvement of at least 3% of body surface area (BSA); OR
 - Psoriasis Area and Severity Index (PASI) score of 10 or greater; OR
 - Incapacitation or serious emotional consequences due to plaque location (i.e., hands, feet, head and neck, genitalia, etc.) or with intractable pruritis; AND
 - Patient did not respond adequately (or is not a candidate) to a 4-week minimum trial of topical agents (i.e., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or vitamin D analogues, etc.); AND
 - Patient did not respond adequately (or is not a candidate) to a 3-month minimum trial of at least one non-biologic systemic agent (i.e., immunosuppressives, retinoic acid derivatives, and/or methotrexate, etc.); AND
 - Patient did not respond adequately (or is not a candidate**) to a 3-month minimum trial of phototherapy (i.e., psoralens with UVA light [PUVA] or UVB with coal tar or dithranol, etc.)
- **Uveitis Associated with Behçet's Syndrome**
 - Must be prescribed by, or in consultation with, a specialist in rheumatology or ophthalmology; AND

- Patient's disease is refractory to immunosuppressive therapy (e.g., corticosteroids, etc.)
- **Graft Versus Host Disease (GVHD)**
 - Patient has received a hematopoietic stem cell transplant; AND
 - Used for steroid-refractory acute GVHD; AND
 - Used in combination with systemic corticosteroids as additional therapy following no response to first-line therapies
- **Management of Immune Checkpoint Inhibitor Related Toxicity**
 - Patient has been receiving therapy with an immune checkpoint inhibitor (e.g., nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, ipilimumab, dostarlimab, etc.); AND
 - Patient has one of the following toxicities related to their immunotherapy:
 - Suspected myocarditis if no improvement after 24-hours of starting pulse-dose methylprednisolone
 - Moderate (grade 2) to severe (grade 3-4) diarrhea or colitis
 - Severe (grade 3-4) pneumonitis refractory to methylprednisolone after 48 hours of therapy
 - Severe (grade 3) or life-threatening (grade 4) acute kidney injury or elevated serum creatinine that is refractory to at least 1 week of therapy with corticosteroids
 - Uveitis (grade 3-4) that is refractory to high-dose systemic corticosteroids
 - Severe inflammatory arthritis as additional disease-modifying therapy if symptoms do not improve within 1 week after starting high-dose corticosteroids or if unable to taper corticosteroids by week 2
 - Moderate, severe, or life-threatening steroid-refractory myalgias or myositis

****Examples of contraindications to phototherapy (PUVA or UVB) include the following:**

- Xeroderma pigmentosum
- Pregnancy or lactation (PUVA only)
- Lupus Erythematosus
- History of one of the following: photosensitivity diseases (e.g., chronic actinic dermatitis, solar urticaria), melanoma, non-melanoma skin cancer, extensive solar damage (PUVA only), treatment with arsenic or ionizing radiation
- Immunosuppression in an organ transplant patient (UVB only)
- Photosensitizing medications (PUVA only)
- Severe liver, renal, or cardiac disease (PUVA only)

- **Renewal Criteria**
 - Patient continues to meet the universal and other indication-specific relevant criteria identified in initial approval criteria; AND
 - Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, malignancy (e.g., lymphoma including hepatosplenic T-Cell lymphoma, skin cancers, cervical cancer, etc.), significant hematologic abnormalities, serious infections (i.e., TB, serious fungal infections, HBV reactivation, etc.), cerebrovascular accidents, cardiotoxicity/heart failure, neurotoxicity, hepatotoxicity, lupus-like syndrome, demyelinating disease, etc.; **AND**
 - **Crohn's Disease:**

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra-intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Crohn's Disease Activity Index (CDAI) score or the Harvey-Bradshaw Index score].
- **Pediatric Crohn's Disease:**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra-intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Pediatric Crohn's Disease Activity Index (PCDAI) score or the Harvey-Bradshaw Index score].
- **Ulcerative Colitis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as stool frequency, rectal bleeding, and/or endoscopic activity, tapering or discontinuation of corticosteroid therapy, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score or the Mayo Score].
- **Pediatric Ulcerative Colitis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as stool frequency, rectal bleeding, and/or endoscopic activity, tapering or discontinuation of corticosteroid therapy, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Pediatric Ulcerative Colitis Activity Index (PUCAI) score or the Mayo Score].
- **Fistulizing Crohn's Disease**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as a reduction in number of enterocutaneous fistulas draining upon gentle compression, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Crohn's Disease Activity Index (CDAI) score or the Harvey-Bradshaw Index score].
- **Psoriatic Arthritis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts and/or an improvement on a disease activity scoring tool [e.g. defined as an improvement in at least 2 of the 4 Psoriatic Arthritis Response Criteria (PsARC), 1 of which must be joint tenderness or swelling score, with no worsening in any of the 4 criteria].
- **Rheumatoid Arthritis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts, reduction of C-reactive protein, improvement of patient global assessment, and/or an improvement on a disease activity scoring tool [e.g. an improvement on a composite scoring index such as Disease Activity Score-28 (DAS28) of 1.2 points or more or a $\geq 20\%$ improvement on the American College of Rheumatology-20 (ACR20) criteria].
- **Ankylosing Spondylitis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as total back pain, physical function, morning stiffness, and/or an improvement on a disease activity scoring tool [e.g. ≥ 1.1 improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS) or an improvement of ≥ 2 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)].

- **Plaque Psoriasis**
 - Disease response as indicated by improvement in signs and symptoms compared to baseline such as redness, thickness, scaliness, and/or the amount of surface area involvement (a total BSA involvement $\leq 1\%$), and/or an improvement on a disease activity scoring tool [e.g. a 75% reduction in the PASI score from when treatment started (PASI 75) or a 50% reduction in the PASI score (PASI 50) and a four-point reduction in the DLQI from when treatment started].
- **Uveitis Associated with Behçet’s Syndrome**
 - Disease response as indicated by an improvement in signs and symptoms compared to baseline [e.g. reduction in inflammation and/or lesions, dose reduction of oral glucocorticoids and/or immunosuppressive agents, improvement in vitreous haze, improvement in best corrected visual acuity (BCVA), disease stability and/or reduced rate of decline].
- **Acute GVHD**
 - May not be renewed (note: requests for continued therapy beyond four doses will be reviewed on a case-by-case basis)
- **Management of Immune Checkpoint Inhibitor Related Toxicity**
 - May not be Renewed

- **Dosage/Administration**

Infliximab			
Indication	Loading Doses	Maintenance Dosing	Maximum Dose & Frequency
Rheumatoid Arthritis	3mg/kg at weeks 0, 2 & 6	3mg/kg every 8 weeks thereafter	Up to 10mg/kg every 4 weeks
Ankylosing Spondylitis	5mg/kg at weeks 0, 2 & 6	5mg/kg every 6 weeks thereafter	5mg/kg every 6 weeks
Crohn’s Disease & Ulcerative Colitis	5mg/kg at weeks 0, 2 & 6	5mg/kg every 8 weeks thereafter	Up to 10mg/kg every 8 weeks
Psoriatic Arthritis, Plaque Psoriasis, Behçet’s Uveitis	5mg/kg at weeks 0, 2 & 6	5mg/kg every 6 weeks thereafter	5mg/kg every 6 weeks
Management of Immune Checkpoint Inhibitor Related Toxicity	5mg/kg at weeks 0, 2	N/A	N/A
Acute GVHD	10mg/kg at week 0, 1, 2 & 3	N/A	N/A

Dose escalation (up to the maximum dose and frequency specified above) may occur upon clinical review on a case-by-case basis provided that the patient has:

- Shown an initial response to therapy; AND
- Received the three loading doses at the dose AND interval specified above; AND
- Received a minimum of one maintenance dose at the dose AND interval specified above; AND
- Responded to therapy (by treatment week 16) with subsequent loss of response; AND
- Dose escalation may either increase the dose OR decrease the interval provided it does not exceed the following limits:
 - Dose increase by no more than 2.5 mg/kg; OR
 - Interval decrease by no more than 2 weeks

Note:

- Prior to escalating doses, a patient's neutralizing IFX-antibodies should be assessed and addition of a DMARD (e.g., thiopurine or MTX), if not already on such therapy, should be considered.

Criteria for disease-specific response to therapy are noted in section IV. Patients with moderate to severe heart failure (NYHA Functional Class III/IV; LVEF \leq 35%) should not receive doses in excess of 5 mg/kg.

HCPCS Code:

- J1745 – Injection, infliximab, excludes biosimilar, 10 mg; 1 billable unit = 10 mg (Includes unbranded biologic)
- Q5103 – Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg; 1 billable unit = 10 mg
- Q5104 – Injection, infliximab-abda, biosimilar, (renflexis), 10 mg; 1 billable unit = 10 mg
- Q5121 – Injection, infliximab-axxq, biosimilar, (avsola), 10 mg; 1 billable unit=10 mg

NDC:

- Remicade 100 mg single-use vial for injection: 57894-0030-xx
- Infliximab 100 mg single-use vial for injection: 57894-0160-xx (Unbranded biologic*)
- Inflectra 100 mg single-use vial: 00069-0809-xx
- Renflexis 100 mg single-use vial: 00006-4305-xx
- Avsola 100 mg single-use vial for injection: 55513-0670-xx

**An unbranded biologic is the same as the brand biologic, Remicade, using the same cell-line as the brand-name reference biologic.*

References:

1. Remicade/Infliximab [package insert]. Horsham, PA; Janssen Biotech, Inc; October 2021. Accessed January 2022.
2. Inflectra [package insert]. Yeonsu-gu, Incheon, Republic of Korea; CELLTRION, Inc; June 2021. Accessed July 2021.
3. Renflexis [package insert]. Yeonsu-gu, Incheon, Republic of Korea; Samsung Bioepis Co., Ltd; February 2021. Accessed July 2021.
4. Avsola [package insert]. Thousand Oaks, CA; Amgen, Inc; December 2019. Accessed July 2021.
5. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2015 Nov 6. doi:10.1002/acr.22783.
6. Ward MM, Deodhar, A, Akl, EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2015 Sep 24. doi: 10.1002/art.39298.
7. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to severe plaque psoriasis. *J Am Acad Dermatol* 2007;56:31e1-15.
8. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. *Rheumatology (Oxford)*. 2007 Jul;46(7):1161-4. Epub 2007 May 3.

9. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. *Rheumatol Int* 2011;31:33–37.
10. Okada A, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. *Arch Ophthalmol* 2012;130(5):592-598.
11. Lichtenstein GR, Loftus EV, Isaacs KL, et al. American College of Gastroenterology. Clinical Guideline: Management of Crohn's disease in adults. *Am J Gastroenterol.* 2018;113:481-517.
12. Kornbluth, A, Sachar, DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol.* 2010 Mar;105(3):501-23.
13. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF- α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology.* 2013 Dec;145(6):1459-63. doi: 10.1053/j.gastro.2013.10.047.
14. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol.* 2012 Jan;148(1):95-102.
15. 15. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J Am Acad Dermatol* 2008 May;58(5):851-64.
16. 16. National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 73 p. (Technology appraisal guidance; no. 195).
17. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis.* 2015 Dec 7. pii: annrheumdis-2015-208337. doi:10.1136/annrheumdis-2015-208337.
18. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* 2017 Mar 6. pii: annrheumdis-2016-210715.
19. Van Der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* doi:10.1136/annrheumdis-2016-210770.
20. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis.* 2017 Jan 28. doi: 10.1093/ecco-jcc/jjx009.
21. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol.* 2000 Oct;130(4):492-513.
22. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology.* 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048.
23. National Institute for Health and Care Excellence. NICE 2012. Crohn's Disease: Management. Published 10 October 2012. Clinical Guideline [CG152]. <https://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085>
24. Lewis JD, Chuai S, Nessel L, et al. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. *Inflamm Bowel Dis.* 2008 Dec; 14(12): 1660–1666. doi: 10.1002/ibd.20520
25. Paine ER. Colonoscopic evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf).* 2014 Aug; 2(3): 161–168.

26. Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. *Nature Reviews Gastroenterology & Hepatology* 13, 567–579 (2016)
doi:10.1038/nrgastro.2016.128
27. Kornbluth, A, Sachar, DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol.* 2010 Mar;105(3):501-23.
28. National Institute for Health and Care Excellence. NICE 2017. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Published 24 May 2017. Technology Appraisal Guidance [TA445].
<https://www.nice.org.uk/guidance/TA445/chapter/1-Recommendations>. Accessed August 2017.
29. National Institute for Health and Care Excellence. NICE 2009. Rheumatoid Arthritis in Adults: Management. Published 25 February 2009. Clinical Guideline [CG79].
<https://www.nice.org.uk/guidance/cg79/resources/rheumatoid-arthritis-in-adultsmanagement-pdf-975636823525>.
30. National Institute for Health and Care Excellence. NICE 2010. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a TNF inhibitor. Published 10 October 2012. Clinical Guideline [TA195].
<https://www.nice.org.uk/guidance/ta195/resources/adalimumab-etanercept-infliximabrituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-atnf-inhibitor-pdf-82598558287813>.
31. Ward MM, Guthri LC, Alba MI. Rheumatoid Arthritis Response Criteria And Patient- Reported Improvement in Arthritis Activity: Is an ACR20 Response Meaningful to Patients”. *Arthritis Rheumatol.* 2014 Sep; 66(9): 2339–2343. doi: 10.1002/art.38705
32. National Institute for Health and Care Excellence. NICE 2008. Infliximab for the treatment of adults with psoriasis. Published 23 January 2008. Technology Appraisal Guidance [TA134].
<https://www.nice.org.uk/guidance/ta134/resources/infliximab-for-the-treatment-ofadults-with-psoriasis-pdf-82598193811141>.
33. Smith CH, Jabbar-Lopez ZK, Yiu ZK, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *Br J Dermatol.* 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665.
34. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol.* 2000 Oct;130(4):492-513.
35. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology.* 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.optha.2013.09.048.
36. Minor DR, Chin K, Sashani-Sabet M, et al. Infliximab in the treatment of anti-CTLA4 antibody (Ipilimumab) induced immune-related colitis. *Cancer Biotherapy & Radiopharmaceuticals.* 2009 June; 24 (3). <https://doi.org/10.1089/cbr.2008.0607>
37. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Translational Lung Cancer Research.* 2015;4(5):560-575. doi:10.3978/j.issn.2218-6751.2015.06.06.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D89.810	Acute graft-versus host disease
D89.812	Acute on chronic graft-versus-host-disease
D89.813	Graft-versus-host disease unspecified
H44.111	Panuveitis, right eye

H44.112	Panuveitis, left eye
H44.113	Panuveitis, bilateral
H44.119	Panuveitis, unspecified eye
I30.8	Other forms of acute pericarditis
I30.9	Acute pericarditis, unspecified
I40.8	Other acute myocarditis
I40.9	Acute myocarditis, unspecified
J70.2	Acute drug-induced interstitial lung disorders
J70.4	Drug-induced interstitial lung disorders, unspecified
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist

M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site

M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip

M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement
M05.8A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site
M06.4	Inflammatory polyarthropathy
M06.8A	Other specific rheumatoid arthritis, other specified site
M60.80	Other myositis, unspecified
M60.811	Other myositis, right shoulder
M60.812	Other myositis, left shoulder
M60.819	Other myositis, unspecified shoulder
M60.821	Other myositis, right upper arm
M60.822	Other myositis, left upper arm
M60.829	Other myositis, unspecified upper arm
M60.821	Other myositis, right upper arm
M60.822	Other myositis, left upper arm
M60.829	Other myositis, unspecified upper arm
M60.831	Other myositis, right forearm
M60.832	Other myositis, left forearm
M60.839	Other myositis, unspecified forearm
M60.841	Other myositis, right hand
M60.842	Other myositis, left hand
M60.849	Other myositis, unspecified hand
M60.851	Other myositis, right thigh
M60.852	Other myositis, left thigh
M60.859	Other myositis, unspecified thigh
M60.861	Other myositis, right lower leg
M60.862	Other myositis, left lower leg
M60.869	Other myositis, unspecified lower leg
M60.871	Other myositis, right ankle and foot
M60.872	Other myositis, left ankle and foot
M60.879	Other myositis, unspecified ankle and foot
M60.88	Other myositis, other site
M60.89	Other myositis, multiple sites

M60.9	Myositis, unspecified
M79.10	Myalgia, unspecified
N17.8	Other acute kidney failure
N17.9	Acute kidney failure, unspecified
R19.7	Diarrhea, unspecified
T86.09	Other complications of bone marrow transplant
Z94.81	Bone marrow transplant status

Please see addendum 1 with additional covered ICD-10 codes, reference: IPD Analytics, LLC. Accessed December 4, 2023.

Addendum 1: Covered ICD-10 Codes Continued

ICD-10-CM Codes for J1745

Please note: CODESOURCE ICD-10-CM information is intended to provide guidance related to current billable ICD-10-CM codes that may be associated with particular drug therapies. It is not intended to replace a healthcare provider's clinical judgement. Off-label ICD-10-CM codes represent those indications where available data supports use. Check with your organization for specific coding requirements.

ICD-10	Description	FDA / Off-Label (Supporting Use)
A51.43	Secondary syphilitic oculopathy	Off-Label
B58.09	Other toxoplasma oculopathy	Off-Label
D86.0	Sarcoidosis of lung	Off-Label
D86.1	Sarcoidosis of lymph nodes	Off-Label
D86.2	Sarcoidosis of lung with sarcoidosis of lymph nodes	Off-Label
D86.3	Sarcoidosis of skin	Off-Label
D86.81	Sarcoid meningitis	Off-Label
D86.82	Multiple cranial nerve palsies in sarcoidosis	Off-Label
D86.83	Sarcoid iridocyclitis	Off-Label
D86.84	Sarcoid pyelonephritis	Off-Label
D86.85	Sarcoid myocarditis	Off-Label
D86.86	Sarcoid arthropathy	Off-Label
D86.87	Sarcoid myositis	Off-Label
D86.89	Sarcoidosis of other sites	Off-Label
D86.9	Sarcoidosis, unspecified	Off-Label
H20.9	Unspecified iridocyclitis	Off-Label
H44.131	Sympathetic uveitis, right eye	Off-Label
H44.132	Sympathetic uveitis, left eye	Off-Label
H44.133	Sympathetic uveitis, bilateral	Off-Label
H44.139	Sympathetic uveitis, unspecified eye	Off-Label
K50.00	Crohn's disease of small intestine without complications	FDA
K50.011	Crohn's disease of small intestine with rectal bleeding	FDA

K50.012	Crohn's disease of small intestine with intestinal obstruction	FDA
K50.013	Crohn's disease of small intestine with fistula	FDA
K50.014	Crohn's disease of small intestine with abscess	FDA
K50.018	Crohn's disease of small intestine with other complication	FDA
K50.019	Crohn's disease of small intestine with unspecified complications	FDA
K50.10	Crohn's disease of large intestine without complications	FDA
K50.111	Crohn's disease of large intestine with rectal bleeding	FDA
K50.112	Crohn's disease of large intestine with intestinal obstruction	FDA
K50.113	Crohn's disease of large intestine with fistula	FDA
K50.114	Crohn's disease of large intestine with abscess	FDA
K50.118	Crohn's disease of large intestine with other complication	FDA
K50.119	Crohn's disease of large intestine with unspecified complications	FDA
K50.80	Crohn's disease of both small and large intestine without complications	FDA
K50.811	Crohn's disease of both small and large intestine with rectal bleeding	FDA
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction	FDA
K50.813	Crohn's disease of both small and large intestine with fistula	FDA
K50.814	Crohn's disease of both small and large intestine with abscess	FDA
K50.818	Crohn's disease of both small and large intestine with other complication	FDA
K50.819	Crohn's disease of both small and large intestine with unspecified complications	FDA
K50.90	Crohn's disease, unspecified, without complications	FDA
K50.911	Crohn's disease, unspecified, with rectal bleeding	FDA
K50.912	Crohn's disease, unspecified, with intestinal obstruction	FDA
K50.913	Crohn's disease, unspecified, with fistula	FDA
K50.914	Crohn's disease, unspecified, with abscess	FDA
K50.918	Crohn's disease, unspecified, with other complication	FDA
K50.919	Crohn's disease, unspecified, with unspecified complications	FDA
K51.00	Ulcerative (chronic) pancolitis without complications	FDA
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding	FDA
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction	FDA
K51.013	Ulcerative (chronic) pancolitis with fistula	FDA
K51.014	Ulcerative (chronic) pancolitis with abscess	FDA

K51.018	Ulcerative (chronic) pancolitis with other complication	FDA
K51.019	Ulcerative (chronic) pancolitis with unspecified complications	FDA
K51.20	Ulcerative (chronic) proctitis without complications	FDA
K51.211	Ulcerative (chronic) proctitis with rectal bleeding	FDA
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction	FDA
K51.213	Ulcerative (chronic) proctitis with fistula	FDA
K51.214	Ulcerative (chronic) proctitis with abscess	FDA
K51.218	Ulcerative (chronic) proctitis with other complication	FDA
K51.219	Ulcerative (chronic) proctitis with unspecified complications	FDA
K51.30	Ulcerative (chronic) rectosigmoiditis without complications	FDA
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding	FDA
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction	FDA
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula	FDA
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess	FDA
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication	FDA
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications	FDA
K51.50	Left sided colitis without complications	FDA
K51.511	Left sided colitis with rectal bleeding	FDA
K51.512	Left sided colitis with intestinal obstruction	FDA
K51.513	Left sided colitis with fistula	FDA
K51.514	Left sided colitis with abscess	FDA
K51.518	Left sided colitis with other complication	FDA
K51.519	Left sided colitis with unspecified complications	FDA
K51.80	Other ulcerative colitis without complications	FDA
K51.811	Other ulcerative colitis with rectal bleeding	FDA
K51.812	Other ulcerative colitis with intestinal obstruction	FDA
K51.813	Other ulcerative colitis with fistula	FDA
K51.814	Other ulcerative colitis with abscess	FDA
K51.818	Other ulcerative colitis with other complication	FDA
K51.819	Other ulcerative colitis with unspecified complications	FDA
K51.90	Ulcerative colitis, unspecified, without complications	FDA
K51.911	Ulcerative colitis, unspecified with rectal bleeding	FDA
K51.912	Ulcerative colitis, unspecified with intestinal obstruction	FDA
K51.913	Ulcerative colitis, unspecified with fistula	FDA
K51.914	Ulcerative colitis, unspecified with abscess	FDA
K51.918	Ulcerative colitis, unspecified with other complication	FDA
K51.919	Ulcerative colitis, unspecified with unspecified complications	FDA

L40.0	Psoriasis vulgaris	FDA
L40.50	Arthropathic psoriasis, unspecified	FDA
L40.51	Distal interphalangeal psoriatic arthropathy	FDA
L40.52	Psoriatic arthritis mutilans	FDA
L40.53	Psoriatic spondylitis	FDA
L40.59	Other psoriatic arthropathy	FDA
L88	Pyoderma gangrenosum	Off-Label
M05.00	Felty's syndrome, unspecified site	FDA
M05.011	Felty's syndrome, right shoulder	FDA
M05.012	Felty's syndrome, left shoulder	FDA
M05.019	Felty's syndrome, unspecified shoulder	FDA
M05.021	Felty's syndrome, right elbow	FDA
M05.022	Felty's syndrome, left elbow	FDA
M05.029	Felty's syndrome, unspecified elbow	FDA
M05.031	Felty's syndrome, right wrist	FDA
M05.032	Felty's syndrome, left wrist	FDA
M05.039	Felty's syndrome, unspecified wrist	FDA
M05.041	Felty's syndrome, right hand	FDA
M05.042	Felty's syndrome, left hand	FDA
M05.049	Felty's syndrome, unspecified hand	FDA
M05.051	Felty's syndrome, right hip	FDA
M05.052	Felty's syndrome, left hip	FDA
M05.059	Felty's syndrome, unspecified hip	FDA
M05.061	Felty's syndrome, right knee	FDA
M05.062	Felty's syndrome, left knee	FDA
M05.069	Felty's syndrome, unspecified knee	FDA
M05.071	Felty's syndrome, right ankle and foot	FDA
M05.072	Felty's syndrome, left ankle and foot	FDA
M05.079	Felty's syndrome, unspecified ankle and foot	FDA
M05.09	Felty's syndrome, multiple sites	FDA
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	FDA
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	FDA
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	FDA
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	FDA
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	FDA
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	FDA
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	FDA
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	FDA

Mo5.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	FDA
Mo5.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	FDA
Mo5.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	FDA
Mo5.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	FDA
Mo5.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	FDA
Mo5.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	FDA
Mo5.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	FDA
Mo5.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	FDA
Mo5.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	FDA
Mo5.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	FDA
Mo5.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	FDA
Mo5.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	FDA
Mo5.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	FDA
Mo5.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	FDA
Mo5.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	FDA
Mo5.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	FDA
Mo5.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	FDA
Mo5.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	FDA
Mo5.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	FDA
Mo5.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	FDA
Mo5.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	FDA
Mo5.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	FDA
Mo5.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	FDA
Mo5.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	FDA

Mo5.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	FDA
Mo5.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	FDA
Mo5.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	FDA
Mo5.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	FDA
Mo5.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	FDA
Mo5.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	FDA
Mo5.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	FDA
Mo5.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	FDA
Mo5.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	FDA
Mo5.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	FDA
Mo5.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	FDA
Mo5.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	FDA
Mo5.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	FDA
Mo5.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	FDA
Mo5.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	FDA
Mo5.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	FDA
Mo5.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	FDA
Mo5.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	FDA
Mo5.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	FDA
Mo5.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	FDA
Mo5.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	FDA
Mo5.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	FDA
Mo5.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	FDA
Mo5.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	FDA

M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	FDA
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	FDA
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	FDA
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	FDA
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	FDA
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	FDA
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	FDA
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	FDA
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	FDA
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	FDA
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	FDA
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	FDA
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	FDA
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	FDA
M05.8A	Other Rheumatoid Arthritis With Rheumatoid Factor Of Other Specified Site	FDA
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	FDA
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	FDA
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	FDA
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	FDA
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	FDA
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	FDA
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	FDA
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	FDA
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	FDA
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	FDA
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	FDA

Mo6.041	Rheumatoid arthritis without rheumatoid factor, right hand	FDA
Mo6.042	Rheumatoid arthritis without rheumatoid factor, left hand	FDA
Mo6.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	FDA
Mo6.051	Rheumatoid arthritis without rheumatoid factor, right hip	FDA
Mo6.052	Rheumatoid arthritis without rheumatoid factor, left hip	FDA
Mo6.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	FDA
Mo6.061	Rheumatoid arthritis without rheumatoid factor, right knee	FDA
Mo6.062	Rheumatoid arthritis without rheumatoid factor, left knee	FDA
Mo6.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	FDA
Mo6.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	FDA
Mo6.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	FDA
Mo6.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	FDA
Mo6.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	FDA
Mo6.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	FDA
Mo6.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	FDA
Mo6.80	Other specified rheumatoid arthritis, unspecified site	FDA
Mo6.811	Other specified rheumatoid arthritis, right shoulder	FDA
Mo6.812	Other specified rheumatoid arthritis, left shoulder	FDA
Mo6.819	Other specified rheumatoid arthritis, unspecified shoulder	FDA
Mo6.821	Other specified rheumatoid arthritis, right elbow	FDA
Mo6.822	Other specified rheumatoid arthritis, left elbow	FDA
Mo6.829	Other specified rheumatoid arthritis, unspecified elbow	FDA
Mo6.831	Other specified rheumatoid arthritis, right wrist	FDA
Mo6.832	Other specified rheumatoid arthritis, left wrist	FDA
Mo6.839	Other specified rheumatoid arthritis, unspecified wrist	FDA
Mo6.841	Other specified rheumatoid arthritis, right hand	FDA
Mo6.842	Other specified rheumatoid arthritis, left hand	FDA
Mo6.849	Other specified rheumatoid arthritis, unspecified hand	FDA
Mo6.851	Other specified rheumatoid arthritis, right hip	FDA
Mo6.852	Other specified rheumatoid arthritis, left hip	FDA
Mo6.859	Other specified rheumatoid arthritis, unspecified hip	FDA
Mo6.861	Other specified rheumatoid arthritis, right knee	FDA

Mo6.862	Other specified rheumatoid arthritis, left knee	FDA
Mo6.869	Other specified rheumatoid arthritis, unspecified knee	FDA
Mo6.871	Other specified rheumatoid arthritis, right ankle and foot	FDA
Mo6.872	Other specified rheumatoid arthritis, left ankle and foot	FDA
Mo6.879	Other specified rheumatoid arthritis, unspecified ankle and foot	FDA
Mo6.88	Other specified rheumatoid arthritis, vertebrae	FDA
Mo6.89	Other specified rheumatoid arthritis, multiple sites	FDA
Mo6.8A	Other specified rheumatoid arthritis, other specified site	FDA
Mo6.9	Rheumatoid arthritis, unspecified	FDA
Mo8.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Off-Label
Mo8.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Off-Label
Mo8.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Off-Label
Mo8.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Off-Label
Mo8.021	Unspecified juvenile rheumatoid arthritis, right elbow	Off-Label
Mo8.022	Unspecified juvenile rheumatoid arthritis, left elbow	Off-Label
Mo8.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Off-Label
Mo8.031	Unspecified juvenile rheumatoid arthritis, right wrist	Off-Label
Mo8.032	Unspecified juvenile rheumatoid arthritis, left wrist	Off-Label
Mo8.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Off-Label
Mo8.041	Unspecified juvenile rheumatoid arthritis, right hand	Off-Label
Mo8.042	Unspecified juvenile rheumatoid arthritis, left hand	Off-Label
Mo8.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Off-Label
Mo8.051	Unspecified juvenile rheumatoid arthritis, right hip	Off-Label
Mo8.052	Unspecified juvenile rheumatoid arthritis, left hip	Off-Label
Mo8.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Off-Label
Mo8.061	Unspecified juvenile rheumatoid arthritis, right knee	Off-Label
Mo8.062	Unspecified juvenile rheumatoid arthritis, left knee	Off-Label
Mo8.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Off-Label
Mo8.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Off-Label
Mo8.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Off-Label
Mo8.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Off-Label
Mo8.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Off-Label

Mo8.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Off-Label
Mo8.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Off-Label
Mo8.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Off-Label
Mo8.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Off-Label
Mo8.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Off-Label
Mo8.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Off-Label
Mo8.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Off-Label
Mo8.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Off-Label
Mo8.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Off-Label
Mo8.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Off-Label
Mo8.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Off-Label
Mo8.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Off-Label
Mo8.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Off-Label
Mo8.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Off-Label
Mo8.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Off-Label
Mo8.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Off-Label
Mo8.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Off-Label
Mo8.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Off-Label
Mo8.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Off-Label
Mo8.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Off-Label
Mo8.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Off-Label
Mo8.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Off-Label
Mo8.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Off-Label
Mo8.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Off-Label
Mo8.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Off-Label

Mo8.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Off-Label
Mo8.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Off-Label
Mo8.3	Juvenile rheumatoid polyarthritis (seronegative)	Off-Label
Mo8.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Off-Label
Mo8.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Off-Label
Mo8.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Off-Label
Mo8.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Off-Label
Mo8.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Off-Label
Mo8.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Off-Label
Mo8.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Off-Label
Mo8.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Off-Label
Mo8.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Off-Label
Mo8.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Off-Label
Mo8.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Off-Label
Mo8.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Off-Label
Mo8.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Off-Label
Mo8.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Off-Label
Mo8.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Off-Label
Mo8.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Off-Label
Mo8.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Off-Label
Mo8.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Off-Label
Mo8.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Off-Label
Mo8.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Off-Label
Mo8.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Off-Label
Mo8.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Off-Label
Mo8.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Off-Label
Mo8.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Off-Label
Mo8.80	Other juvenile arthritis, unspecified site	Off-Label
Mo8.811	Other juvenile arthritis, right shoulder	Off-Label
Mo8.812	Other juvenile arthritis, left shoulder	Off-Label
Mo8.819	Other juvenile arthritis, unspecified shoulder	Off-Label

Mo8.821	Other juvenile arthritis, right elbow	Off-Label
Mo8.822	Other juvenile arthritis, left elbow	Off-Label
Mo8.829	Other juvenile arthritis, unspecified elbow	Off-Label
Mo8.831	Other juvenile arthritis, right wrist	Off-Label
Mo8.832	Other juvenile arthritis, left wrist	Off-Label
Mo8.839	Other juvenile arthritis, unspecified wrist	Off-Label
Mo8.841	Other juvenile arthritis, right hand	Off-Label
Mo8.842	Other juvenile arthritis, left hand	Off-Label
Mo8.849	Other juvenile arthritis, unspecified hand	Off-Label
Mo8.851	Other juvenile arthritis, right hip	Off-Label
Mo8.852	Other juvenile arthritis, left hip	Off-Label
Mo8.859	Other juvenile arthritis, unspecified hip	Off-Label
Mo8.861	Other juvenile arthritis, right knee	Off-Label
Mo8.862	Other juvenile arthritis, left knee	Off-Label
Mo8.869	Other juvenile arthritis, unspecified knee	Off-Label
Mo8.871	Other juvenile arthritis, right ankle and foot	Off-Label
Mo8.872	Other juvenile arthritis, left ankle and foot	Off-Label
Mo8.879	Other juvenile arthritis, unspecified ankle and foot	Off-Label
Mo8.88	Other juvenile arthritis, vertebrae	Off-Label
Mo8.89	Other juvenile arthritis, multiple sites	Off-Label
Mo8.90	Juvenile arthritis, unspecified, unspecified site	Off-Label
Mo8.911	Juvenile arthritis, unspecified, right shoulder	Off-Label
Mo8.912	Juvenile arthritis, unspecified, left shoulder	Off-Label
Mo8.919	Juvenile arthritis, unspecified, unspecified shoulder	Off-Label
Mo8.921	Juvenile arthritis, unspecified, right elbow	Off-Label
Mo8.922	Juvenile arthritis, unspecified, left elbow	Off-Label
Mo8.929	Juvenile arthritis, unspecified, unspecified elbow	Off-Label
Mo8.931	Juvenile arthritis, unspecified, right wrist	Off-Label
Mo8.932	Juvenile arthritis, unspecified, left wrist	Off-Label
Mo8.939	Juvenile arthritis, unspecified, unspecified wrist	Off-Label
Mo8.941	Juvenile arthritis, unspecified, right hand	Off-Label
Mo8.942	Juvenile arthritis, unspecified, left hand	Off-Label
Mo8.949	Juvenile arthritis, unspecified, unspecified hand	Off-Label
Mo8.951	Juvenile arthritis, unspecified, right hip	Off-Label
Mo8.952	Juvenile arthritis, unspecified, left hip	Off-Label
Mo8.959	Juvenile arthritis, unspecified, unspecified hip	Off-Label
Mo8.961	Juvenile arthritis, unspecified, right knee	Off-Label
Mo8.962	Juvenile arthritis, unspecified, left knee	Off-Label
Mo8.969	Juvenile arthritis, unspecified, unspecified knee	Off-Label
Mo8.971	Juvenile arthritis, unspecified, right ankle and foot	Off-Label
Mo8.972	Juvenile arthritis, unspecified, left ankle and foot	Off-Label
Mo8.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Off-Label
Mo8.98	Juvenile arthritis, unspecified, vertebrae	Off-Label
Mo8.99	Juvenile arthritis, unspecified, multiple sites	Off-Label

M08.9A	Juvenile arthritis, unspecified, other specified site	Off-Label
M30.3	Mucocutaneous lymph node syndrome	Off-Label
M35.2	Behçet's disease	Off-Label
M35.81	Multisystem inflammatory syndrome	Off-Label
M35.89	Other specified systemic involvement of connective tissue	Off-Label
M45.0	Ankylosing spondylitis of multiple sites in spine	FDA
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	FDA
M45.2	Ankylosing spondylitis of cervical region	FDA
M45.3	Ankylosing spondylitis of cervicothoracic region	FDA
M45.4	Ankylosing spondylitis of thoracic region	FDA
M45.5	Ankylosing spondylitis of thoracolumbar region	FDA
M45.6	Ankylosing spondylitis lumbar region	FDA
M45.7	Ankylosing spondylitis of lumbosacral region	FDA
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	FDA
M45.9	Ankylosing spondylitis of unspecified sites in spine	FDA
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter	Off-Label
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter	Off-Label
U07.1	COVID-19	Off-Label